334
EPIGENETIC MEMORY OF INTESTINAL EPITHELIAL CELLS IN INFLAMMATORY BOWEL DISEASE
Date
May 19, 2024
Tracks
Related Products
EPIGENETIC SILENCING OF A LATENT TH17-LIKE PROGRAM IN HUMAN TREGS
BACKGROUND: Loss of the suppressive function of helper T regulatory cells (Tregs) can promote uncontrolled inflammation in Crohn’s Disease (CD)…
INTEGRATED MULTIOMICS MARKERS HIGHLIGHT DISTINCT MICROBIAL PATHWAYS LINKED TO ICI EFFICACY AND ADVERSE EVENTS
BACKGROUND: Immune activation by immune checkpoint inhibitors (ICI) has shown promise in the treatment of diverse cancer types at the cost of different immune-related adverse events (irAEs)…
NOVEL PLATFORMS FOR IDENTIFYING AND TESTING SMALL MOLECULE DRUG BASED TREATMENTS FOR INFLAMMATORY BOWEL DISEASE.
BACKGROUND: Tofacitinib and upadacitinib are JAK inhibitors (JAKi) approved for Inflammatory Bowel Disease (IBD) treatment. Response rates to JAKi in IBD are varied, and there are concerns for serious side effects like venous thromboembolism, cancer and cardiovascular events…
VALIDATION OF COPY NUMBER ABERRATION AND METHYLATED DNA MARKERS FOR DIFFERENTIATION OF NON-DYSPLASTIC BARRETT’S ESOPHAGUS FROM BARRETT’S ESOPHAGUS WITH HIGH GRADE DYSPLASIA AND ESOPHAGEAL ADENOCARCINOMA : A MULTICENTER STUDY
Endoscopic surveillance of Barrett’s esophagus (BE) is recommended to identify dysplasia (low grade [LGD], high grade [HGD]) or adenocarcinoma [EAC]) for endoscopic intervention. However, this paradigm is limited by sampling error and subtle endoscopic changes, leading to missed HGD and EAC…